Welcome to Stayble Therapeutics AB´s IR pages
Stayble Therapeutics is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. STA363 is intended for patients not improving after treatment with analgesics and physiotherapy.
LATEST PRESS RELEASES
The Subscription Period for the Warrants of Series TO1 in Stayble Therapeutics AB begins Today October 17, 2020
Today is the first day of exercise TO1 for subsription to company shares that extend to December 1, 2020. Every one warrent gives the right to subscribe one new share in the Company to an exercise pri...
The Exercise Price for the Warrants of Series TO1 in Stayble Therapeutics AB has been set to SEK 12,30
Stayble Theraputics AB carried out during the first quarter of 2020 in conection with the listing on Nasdaq First North Growt Market, an issue of units where one unit consisted of one newly issued sha...